文献速递骨软组织肉瘤与黑色素瘤

欧洲转移性黑色素瘤新型治疗可及性更新——2024年欧洲黑色素瘤登记处与欧洲皮肤肿瘤协会调查

An update on access to novel treatment for metastatic melanoma in Europe - A 2024 survey of the European melanoma registry and the European association of dermato-oncology.
PubMed 文献 · Eur J Cancer · 2024-11-16

欧洲皮肤肿瘤协会与欧洲黑色素瘤登记处于2022年2月至4月及2024年2月至4月对27个欧洲国家的黑色素瘤专家进行网络调查,评估一线及辅助治疗的注册与报销情况。结果显示BRAFi/MEKi、抗PD1、抗PD1/抗CTLA4联合治疗的可及性较2017年显著改善,但抗PD1/抗CTLA4联合免疫治疗在48%的国家仍存在限制。

要点

  • BRAFi/MEKi、抗PD1、抗PD1/抗CTLA4注册报销比例从2017年48%、63%、37%升至2024年96%、96%、78%。
  • 抗PD1/抗CTLA4联合免疫治疗在48%受访国家仍不能无限制获得。
  • 纳武利尤单抗/瑞拉利单抗仅获批用于PDL-1阴性黑色素瘤,在7个欧洲国家报销。

核心结论

  • 欧洲转移性黑色素瘤治疗的报销已有改善,但仍存在挑战和差异,需要在欧洲和全球层面进一步努力协调和改善抗癌药物可及性。

研究设计与样本

  • 欧洲皮肤肿瘤协会与欧洲黑色素瘤登记处开展的网络调查,使用LimeSurvey于2022年2月至4月发放给27个欧洲国家的黑色素瘤专家,并于2024年2月至4月更新。

主要发现

  • BRAFi/MEKi、抗PD1、抗PD1/抗CTLA4治疗的注册和报销比例分别从2017年的48%、63%、37%增至2024年的96%、96%、78%。
  • 抗PD1/抗CTLA4联合免疫治疗在48%的受访国家仍不能无限制获得。
  • 纳武利尤单抗/瑞拉利单抗联合仅获批用于PDL-1阴性黑色素瘤,在欧洲7个国家报销。
  • Tebentafusp在15个国家报销,talimogene laherpervec在5个国家报销。
  • 2024年III期黑色素瘤辅助治疗中,达拉非尼/曲美替尼在22个国家报销,抗PD1抗体在27个国家中的24个报销;IIB/IIC期疾病中帕博利珠单抗和纳武利尤单抗分别在15和8个国家报销。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Advances in cancer treatments have significantly improved their effectiveness, yet access to first-line therapies remains limited. A 2017 survey revealed that over 25 % of metastatic melanoma patients in Europe lacked access to recommended therapies. To address this, the European Association of Dermato-Oncology and the European Melanoma Registry conducted a follow-up study on the registration and reimbursement of first-line treatments.A web-based survey using LimeSurvey was distributed to melanoma experts across 27 European countries from February to April 2022 and updated from February to April 2024. The questionnaire covered the percentage of patients receiving recommended treatments, as well as treatment authorization and reimbursement dates for systemic and adjuvant therapies.There has been significant improvement in the registration and reimbursement of BRAFi/MEKi, anti-PD1, and anti-PD1/anti-CTLA4 therapies, increasing from 48 %, 63 %, and 37 % in 2017 to 96 %, 96 %, and 78 % in 2024, respectively. Despite these gains, restrictions persist. Anti-PD1/anti-CTLA4 combination immunotherapy is still not available without restrictions in 48 % of the surveyed countries. The nivolumab/relatlimab combination is licensed only for PDL-1-negative melanoma and reimbursed in seven countries of Europe. Tebentafusp is reimbursed in 15 countries and talimogene laherpervec in 5. In 2024, adjuvant treatments for stage III melanoma are reimbursed in 22 countries for dabrafenib/trametinib and 24 of 27 for anti-PD1 antibodies. Pembrolizumab and nivolumab are reimbursed in 15 and 8 countries, respectively, for stage IIB/IIC disease.While there have been improvements in the reimbursement of metastatic melanoma treatments in Europe, challenges and discrepancies remain. Further efforts at European and global levels are needed to harmonize and enhance access to cancer medicines.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Kandolf L, Ascierto PA, Bastholt L, et al. An update on access to novel treatment for metastatic melanoma in Europe - A 2024 survey of the European melanoma registry and the European association of dermato-oncology. Eur J Cancer. 2024. PMID: 39721295. doi:10.1016/j.ejca.2024.115124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。